MRSA(メチシリン耐性黄色ブドウ球菌)薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global MRSA Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Key buying criteria

PART 06: Antibacterial: Overview
• Introduction
• MOA
• General principles for use of antibiotics
• Clinical uses

PART 07: Antimicrobial resistance
• Sources of spread of resistant organisms
• Initiatives to improve antibiotic innovation
• Surveillance systems for antibiotic resistance

PART 08: Legislation relating to antibiotics use in US

PART 09: Pipeline analysis
• Solithromycin
• TD-1792
• Baxdela
• Taksta

PART 10: Market landscape
• Global antibacterial drugs market
• Global MRSA drugs market
• Five forces analysis

PART 11: Market segmentation by drug class
• Tetracycline
• Folate antagonists
• Cephalosporin
• Lipopeptide
• Oxazolidinone
• Lipoglycopeptide

PART 12: Market segmentation by drug origin
• Semisynthetic drugs
• Synthetic drugs

PART 13: Market segmentation by MOA
• Bacteriostatic
• Bactericidal

PART 14: Geographical segmentation
• Global MRSA drugs market by geographical segmentation 2015-2020
• MRSA drugs market in Americas
• MRSA drugs market in EMEA
• MRSA drugs market in APAC

PART 15: Market drivers
• Special regulatory designations
• Increasing prevalence of infections
• Growing awareness of diseases
• Rise in older population

PART 16: Impact of drivers

PART 17: Market challenges
• Development of drug-resistant strains
• Patent expiries and generic penetration
• Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Strategic alliances and M&A
• Patient assistance programs
• Increased funding for antibiotic research

PART 20: Vendor landscape
• Competitive scenario
• Key vendor profiles
• Allergan
• Merck
• Pfizer
• Theravance
• Other prominent vendors

PART 21: Appendix
• List of abbreviations

PART 22: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Percentage of MRSA infections among Staphylococcus infections in US 2015
Exhibit 03: Percentage of MRSA infections in US based on type 2015
Exhibit 04: Sites of Staphylococcus infections
Exhibit 05: Key buying criteria for MRSA drugs
Exhibit 06: MOA of antibacterial drugs
Exhibit 07: General principles involved in use of antibiotics
Exhibit 08: Causes of AMR
Exhibit 09: Sources of spread of resistant organisms
Exhibit 10: Estimated deaths per year caused by AMR in 2050
Exhibit 11: Initiatives improving antibiotic innovation
Exhibit 12: Surveillance systems of various countries
Exhibit 13: Legislation relating to antibiotics use in US
Exhibit 14: Pipeline portfolio: Global MRSA drugs market
Exhibit 15: Global antibacterial drugs market 2015-2020 ($ billions)
Exhibit 16: Market share of global MRSA drugs in global pharmaceutical market 2015
Exhibit 17: Global MRSA drugs market 2015-2020 ($ billions)
Exhibit 18: Five forces analysis
Exhibit 19: Cephalosporin segmentation by generation of drugs
Exhibit 20: Global MRSA drugs market segmentation based on volume 2015
Exhibit 21: Global MRSA drugs market segmentation by drug origin
Exhibit 22: Global MRSA drugs market segmentation by geography 2015
Exhibit 23: Global MRSA drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 24: Percentage share of global MRSA drugs market by geography 2015-2020
Exhibit 25: MRSA drugs market in Americas 2015-2020 ($ billions)
Exhibit 26: Percentage share of MRSA drugs market in US 2015
Exhibit 27: MRSA drugs market in EMEA 2015-2020 ($ millions)
Exhibit 28: MRSA drugs market in APAC 2015-2020 ($ millions)
Exhibit 29: Global MRSA drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 30: Percentage of MRSA infections 2014
Exhibit 31: Impact of drivers
Exhibit 32: Antibiotic-resistant strains of Staphylococcus according to period of development of resistance
Exhibit 33: Ranking for top ten countries based on antibiotic consumption in livestock 2015
Exhibit 34: Antibacterial drug approvals by FDA and EMA
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Allergan: Key takeaways
Exhibit 37: Merck: YoY revenue and growth rate of Cubicin 2013-2015 ($ billion)
Exhibit 38: Merck: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Zyvox 2013-2015 ($ millions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Tygacil 2013-2015 ($ millions)
Exhibit 41: Pfizer: Key takeaways
Exhibit 42: Theravance Biopharma: YoY revenue comparison of Vibativ 2014-2015 ($ millions)
Exhibit 43: Theravance: Key takeaways


【レポート販売概要】

■ タイトル:MRSA(メチシリン耐性黄色ブドウ球菌)薬の世界市場2016-2020
■ 英文:Global MRSA Drugs Market 2016-2020
■ 発行日:2016年7月27日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9071
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。